From Phase I In Australia To A Global Phase III

In 2018, a publicly listed biotech company based in California specializing in oncology drug development needed a Phase I rescue study with two sites in Australia. At the time, the sponsor needed to be saved from a global CRO, because of poor performance and cultural misfit.

Over the next few years, the sponsor would continue to contract with the new CRO that rescued them from their study Phase I/II and Phase II clinical trials with sites in Australia, New Zealand, Malaysia, South Korea, Taiwan, Thailand, Singapore, Hong Kong, and other areas in APAC. See how after receiving further aid, the sponsor was also able to get its patients on treatment and identify additional opportunities to streamline processes and leverage document/process standards.